Context-dependent antagonism between Akt inhibitors and topoisomerase poisons

Marina Gálvez-Peralta, Karen S. Flatten, David A. Loegering, Kevin L. Peterson, Paula A. Schneider, Charles Erlichman, Scott H Kaufmann

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Signaling through the phosphatidylinositol-3 kinase (PI3K)/Akt pathway, which is aberrantly activated in >50% of carcinomas, inhibits apoptosis and contributes to drug resistance. Accordingly, several Akt inhibitors are currently undergoing preclinical or early clinical testing. To examine the effect of Akt inhibition on the activity of multiple widely used classes of antineoplastic agents, human cancer cell lines were treated with the Akt inhibitor A-443654 [(2S)-1-(1H-indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl) pyridin-3-yl] oxypropan-2-amine; ATP-competitive] or MK-2206 (8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6] naphthyridin-3-one;dihydrochloride; allosteric inhibitor) or with small interfering RNA (siRNA) targeting phosphoinositide-dependent kinase 1 (PDK1) along with cisplatin, melphalan, camptothecin, or etoposide and assayed for colony formation. Surprisingly different results were observed when Akt inhibitors were combined with different drugs. Synergistic effects were observed in multiple cell lines independent of PI3K pathway status when A-443654 or MK-2206 was combined with the DNA cross-linking agents cisplatin or melphalan. In contrast, effects of the Akt inhibitors in combination with camptothecin or etoposide were more complicated. In HCT116 and DLD1 cells, which harbor activating PI3KCA mutations, A-443654 over a broad concentration range enhanced the effects of camptothecin or etoposide. In contrast, in cell lines lacking activating PI3KCA mutations, partial inhibition of Akt signaling synergized with camptothecin or etoposide, but higher A-443654 or MK-2206 concentrations (>80% inhibition of Akt signaling) or PDK1 siRNA antagonized the topoisomerase poisons by diminishing DNA synthesis, a process that contributes to effective DNA damage and killing by these agents. These results indicate that the effects of combining inhibitors of the PI3K/Akt pathway with certain classes of chemotherapeutic agents might be more complicated than previously recognized.

Original languageEnglish (US)
Pages (from-to)723-734
Number of pages12
JournalMolecular Pharmacology
Volume85
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Topoisomerase Inhibitors
Camptothecin
Poisons
Phosphatidylinositol 3-Kinase
Etoposide
Melphalan
1-Phosphatidylinositol 4-Kinase
Cell Line
Small Interfering RNA
Cisplatin
HCT116 Cells
Mutation
DNA
Drug Resistance
Antineoplastic Agents
DNA Damage
Amines
Adenosine Triphosphate
Apoptosis
Carcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Gálvez-Peralta, M., Flatten, K. S., Loegering, D. A., Peterson, K. L., Schneider, P. A., Erlichman, C., & Kaufmann, S. H. (2014). Context-dependent antagonism between Akt inhibitors and topoisomerase poisons. Molecular Pharmacology, 85(5), 723-734. https://doi.org/10.1124/mol.113.088674

Context-dependent antagonism between Akt inhibitors and topoisomerase poisons. / Gálvez-Peralta, Marina; Flatten, Karen S.; Loegering, David A.; Peterson, Kevin L.; Schneider, Paula A.; Erlichman, Charles; Kaufmann, Scott H.

In: Molecular Pharmacology, Vol. 85, No. 5, 2014, p. 723-734.

Research output: Contribution to journalArticle

Gálvez-Peralta, M, Flatten, KS, Loegering, DA, Peterson, KL, Schneider, PA, Erlichman, C & Kaufmann, SH 2014, 'Context-dependent antagonism between Akt inhibitors and topoisomerase poisons', Molecular Pharmacology, vol. 85, no. 5, pp. 723-734. https://doi.org/10.1124/mol.113.088674
Gálvez-Peralta M, Flatten KS, Loegering DA, Peterson KL, Schneider PA, Erlichman C et al. Context-dependent antagonism between Akt inhibitors and topoisomerase poisons. Molecular Pharmacology. 2014;85(5):723-734. https://doi.org/10.1124/mol.113.088674
Gálvez-Peralta, Marina ; Flatten, Karen S. ; Loegering, David A. ; Peterson, Kevin L. ; Schneider, Paula A. ; Erlichman, Charles ; Kaufmann, Scott H. / Context-dependent antagonism between Akt inhibitors and topoisomerase poisons. In: Molecular Pharmacology. 2014 ; Vol. 85, No. 5. pp. 723-734.
@article{b2907e7fa62c45fcbfacbdbcb99276f9,
title = "Context-dependent antagonism between Akt inhibitors and topoisomerase poisons",
abstract = "Signaling through the phosphatidylinositol-3 kinase (PI3K)/Akt pathway, which is aberrantly activated in >50{\%} of carcinomas, inhibits apoptosis and contributes to drug resistance. Accordingly, several Akt inhibitors are currently undergoing preclinical or early clinical testing. To examine the effect of Akt inhibition on the activity of multiple widely used classes of antineoplastic agents, human cancer cell lines were treated with the Akt inhibitor A-443654 [(2S)-1-(1H-indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl) pyridin-3-yl] oxypropan-2-amine; ATP-competitive] or MK-2206 (8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6] naphthyridin-3-one;dihydrochloride; allosteric inhibitor) or with small interfering RNA (siRNA) targeting phosphoinositide-dependent kinase 1 (PDK1) along with cisplatin, melphalan, camptothecin, or etoposide and assayed for colony formation. Surprisingly different results were observed when Akt inhibitors were combined with different drugs. Synergistic effects were observed in multiple cell lines independent of PI3K pathway status when A-443654 or MK-2206 was combined with the DNA cross-linking agents cisplatin or melphalan. In contrast, effects of the Akt inhibitors in combination with camptothecin or etoposide were more complicated. In HCT116 and DLD1 cells, which harbor activating PI3KCA mutations, A-443654 over a broad concentration range enhanced the effects of camptothecin or etoposide. In contrast, in cell lines lacking activating PI3KCA mutations, partial inhibition of Akt signaling synergized with camptothecin or etoposide, but higher A-443654 or MK-2206 concentrations (>80{\%} inhibition of Akt signaling) or PDK1 siRNA antagonized the topoisomerase poisons by diminishing DNA synthesis, a process that contributes to effective DNA damage and killing by these agents. These results indicate that the effects of combining inhibitors of the PI3K/Akt pathway with certain classes of chemotherapeutic agents might be more complicated than previously recognized.",
author = "Marina G{\'a}lvez-Peralta and Flatten, {Karen S.} and Loegering, {David A.} and Peterson, {Kevin L.} and Schneider, {Paula A.} and Charles Erlichman and Kaufmann, {Scott H}",
year = "2014",
doi = "10.1124/mol.113.088674",
language = "English (US)",
volume = "85",
pages = "723--734",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

TY - JOUR

T1 - Context-dependent antagonism between Akt inhibitors and topoisomerase poisons

AU - Gálvez-Peralta, Marina

AU - Flatten, Karen S.

AU - Loegering, David A.

AU - Peterson, Kevin L.

AU - Schneider, Paula A.

AU - Erlichman, Charles

AU - Kaufmann, Scott H

PY - 2014

Y1 - 2014

N2 - Signaling through the phosphatidylinositol-3 kinase (PI3K)/Akt pathway, which is aberrantly activated in >50% of carcinomas, inhibits apoptosis and contributes to drug resistance. Accordingly, several Akt inhibitors are currently undergoing preclinical or early clinical testing. To examine the effect of Akt inhibition on the activity of multiple widely used classes of antineoplastic agents, human cancer cell lines were treated with the Akt inhibitor A-443654 [(2S)-1-(1H-indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl) pyridin-3-yl] oxypropan-2-amine; ATP-competitive] or MK-2206 (8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6] naphthyridin-3-one;dihydrochloride; allosteric inhibitor) or with small interfering RNA (siRNA) targeting phosphoinositide-dependent kinase 1 (PDK1) along with cisplatin, melphalan, camptothecin, or etoposide and assayed for colony formation. Surprisingly different results were observed when Akt inhibitors were combined with different drugs. Synergistic effects were observed in multiple cell lines independent of PI3K pathway status when A-443654 or MK-2206 was combined with the DNA cross-linking agents cisplatin or melphalan. In contrast, effects of the Akt inhibitors in combination with camptothecin or etoposide were more complicated. In HCT116 and DLD1 cells, which harbor activating PI3KCA mutations, A-443654 over a broad concentration range enhanced the effects of camptothecin or etoposide. In contrast, in cell lines lacking activating PI3KCA mutations, partial inhibition of Akt signaling synergized with camptothecin or etoposide, but higher A-443654 or MK-2206 concentrations (>80% inhibition of Akt signaling) or PDK1 siRNA antagonized the topoisomerase poisons by diminishing DNA synthesis, a process that contributes to effective DNA damage and killing by these agents. These results indicate that the effects of combining inhibitors of the PI3K/Akt pathway with certain classes of chemotherapeutic agents might be more complicated than previously recognized.

AB - Signaling through the phosphatidylinositol-3 kinase (PI3K)/Akt pathway, which is aberrantly activated in >50% of carcinomas, inhibits apoptosis and contributes to drug resistance. Accordingly, several Akt inhibitors are currently undergoing preclinical or early clinical testing. To examine the effect of Akt inhibition on the activity of multiple widely used classes of antineoplastic agents, human cancer cell lines were treated with the Akt inhibitor A-443654 [(2S)-1-(1H-indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl) pyridin-3-yl] oxypropan-2-amine; ATP-competitive] or MK-2206 (8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6] naphthyridin-3-one;dihydrochloride; allosteric inhibitor) or with small interfering RNA (siRNA) targeting phosphoinositide-dependent kinase 1 (PDK1) along with cisplatin, melphalan, camptothecin, or etoposide and assayed for colony formation. Surprisingly different results were observed when Akt inhibitors were combined with different drugs. Synergistic effects were observed in multiple cell lines independent of PI3K pathway status when A-443654 or MK-2206 was combined with the DNA cross-linking agents cisplatin or melphalan. In contrast, effects of the Akt inhibitors in combination with camptothecin or etoposide were more complicated. In HCT116 and DLD1 cells, which harbor activating PI3KCA mutations, A-443654 over a broad concentration range enhanced the effects of camptothecin or etoposide. In contrast, in cell lines lacking activating PI3KCA mutations, partial inhibition of Akt signaling synergized with camptothecin or etoposide, but higher A-443654 or MK-2206 concentrations (>80% inhibition of Akt signaling) or PDK1 siRNA antagonized the topoisomerase poisons by diminishing DNA synthesis, a process that contributes to effective DNA damage and killing by these agents. These results indicate that the effects of combining inhibitors of the PI3K/Akt pathway with certain classes of chemotherapeutic agents might be more complicated than previously recognized.

UR - http://www.scopus.com/inward/record.url?scp=84897465284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897465284&partnerID=8YFLogxK

U2 - 10.1124/mol.113.088674

DO - 10.1124/mol.113.088674

M3 - Article

C2 - 24569089

AN - SCOPUS:84897465284

VL - 85

SP - 723

EP - 734

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -